{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:20:11Z","timestamp":1740122411355,"version":"3.37.3"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"DOI":"10.1007\/s10840-023-01502-2","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T08:02:51Z","timestamp":1676534571000},"page":"1547-1548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Catheter ablation as first-line therapy for ventricular tachycardia: is it time for a paradigm shift?"],"prefix":"10.1007","volume":"66","author":[{"given":"Maiwand","family":"Mirwais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3155-2006","authenticated-orcid":false,"given":"Timothy M.","family":"Markman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"issue":"25","key":"1502_CR1","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.122.059598","volume":"145","author":"P Della Bella","year":"2022","unstructured":"Della Bella P, Baratto F, Vergara P, et al. Does timing of ventricular tachycardia ablation affect prognosis in patients with an implantable cardioverter defibrillator? Results From the Multicenter Randomized PARTITA Trial. Circulation. 2022;145(25):1829\u201338. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059598.","journal-title":"Circulation"},{"key":"1502_CR2","doi-asserted-by":"publisher","unstructured":"Tung R, Xue Y, Chen M, et al. First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation: the PAUSE-SCD Randomized Trial. Circulation. Published online June 21, 2022. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060039.","DOI":"10.1161\/CIRCULATIONAHA.122.060039"},{"issue":"12","key":"1502_CR3","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.hrthm.2022.07.005","volume":"19","author":"N Prasitlumkum","year":"2022","unstructured":"Prasitlumkum N, Navaravong L, Desai A, et al. Impact of early ventricular tachycardia ablation in patients with an implantable cardioverter-defibrillator: an updated systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2022;19(12):2054\u201361. https:\/\/doi.org\/10.1016\/j.hrthm.2022.07.005.","journal-title":"Heart Rhythm"},{"key":"1502_CR4","doi-asserted-by":"publisher","unstructured":"Kotake Y, Huang K, et al. Efficacy and safety of catheter ablation as first-line therapy for the management of ventricular tachycardia. JICE. 2023. https:\/\/doi.org\/10.1007\/s10840-023-01483-2.","DOI":"10.1007\/s10840-023-01483-2"},{"issue":"12","key":"1502_CR5","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.hrthm.2022.07.024","volume":"19","author":"M Mirwais","year":"2022","unstructured":"Mirwais M, Supple GE. Early ventricular tachycardia ablation: for some, but not for all? Heart Rhythm. 2022;19(12):2062\u20133. https:\/\/doi.org\/10.1016\/j.hrthm.2022.07.024.","journal-title":"Heart Rhythm"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-023-01502-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-023-01502-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-023-01502-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:09:43Z","timestamp":1696313383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-023-01502-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":5,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["1502"],"URL":"https:\/\/doi.org\/10.1007\/s10840-023-01502-2","relation":{},"ISSN":["1572-8595"],"issn-type":[{"type":"electronic","value":"1572-8595"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"assertion":[{"value":"28 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TM has served as a consultant for Medtronic and has received speaking fees from Boston Scientific. MM has nothing relevant to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}